Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Apple Restores Telegram to App Store After Content Policy Violation 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
CINCINNATI, April 04, 2018 -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its second quarter fiscal 2018 operating results before the NASDAQ market opens on Thursday, April 26, 2018. The release will be available shortly thereafter on Meridian’s website at www.meridianbioscience.com.
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Many companies also utilize Meridian’s products as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
Contact:
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: [email protected]
